Clinical characteristics of patients who developed an infection during immunosuppressive treatment
| No. (%) | |||
|---|---|---|---|
| Clinical characteristics | Infectionn = 29 | No infectionn = 50 | P |
| Cancer stagea | 0.386 | ||
| Stage III | 4 (14) | 12 (24) | |
| Stage IV | 24 (86) | 37 (76) | |
| Malignancy type | 0.752 | ||
| Melanoma | 19 (66) | 36 (72) | |
| Solid tumor | 10 (34) | 13 (26) | |
| Hematologic | 0 (0) | 1 (2) | |
| Immune checkpoint inhibitor type | 0.758 | ||
| Anti-CTLA-4 | 25 (86) | 41 (82) | |
| Anti-PD-1/L1 | 4 (14) | 9 (18) | |
| Treatment for diarrhea or colitis | 0.483 | ||
| Steroids alone | 18 (62) | 26 (52) | |
| Steroids + infliximab | 11 (38) | 24 (48) | |
| Mean length of steroid use (days, SD) | 80.4 (116) | 46.7 (34.5) | 0.063 |
| Length of steroid use | 0.160 | ||
| Short duration (≤ 30 days) | 8 (28) | 22 (44) | |
| Long duration (> 30 days) | 21 (72) | 28 (56) | |
| Diarrhea grade | 0.353 | ||
| Grade 1 | 3 (10) | 10 (20) | |
| Grade 2–4 | 26 (90) | 40 (80) | |
| Colitis grade | 1.000 | ||
| Grade 1 | 11 (38) | 19 (38) | |
| Grade 2–3 | 18 (62) | 31 (62) | |
Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein-4; PD-1/L1, Programmed death-1/ligand 1; SD, standard deviation
aStage of cancer was documented in 28 patients with infection and 49 patients with no infection